These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30281011)

  • 1. Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer.
    Zillioux J; DiLizia M; Schaheen B; Rustin R; Krupski TL
    Can J Urol; 2018 Oct; 25(5):9525-9526. PubMed ID: 30281011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    Dhariwal R; Pindoria N; Dasgupta P; Khan MS
    BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
    [No Abstract]   [Full Text] [Related]  

  • 3. Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report.
    Badheeb A; Alkhanbashi O; Rakrouki S; Mahmood T; Alqannas M; Badheeb M; Ahmed F
    Pan Afr Med J; 2022; 42():98. PubMed ID: 36034031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatments for patients with progressive metastatic urothelial carcinoma.
    Rosenberg JE
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
    [No Abstract]   [Full Text] [Related]  

  • 5. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab in urothelial bladder carcinoma.
    Hamilou Z; Lavaud P; Loriot Y
    Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
    Küronya Z; Danyi T; Balatoni T; Liszkay G; Tóth E; Biró K; Géczi L
    J Med Case Rep; 2022 Oct; 16(1):396. PubMed ID: 36316780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Patel R; Bock M; Polotti CF; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma.
    Turner N; Leventhal J
    Int J Dermatol; 2018 Oct; 57(10):e90-e92. PubMed ID: 30091457
    [No Abstract]   [Full Text] [Related]  

  • 14. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
    J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
    [No Abstract]   [Full Text] [Related]  

  • 18. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
    Le Brun IC; Benderra MA
    Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742
    [No Abstract]   [Full Text] [Related]  

  • 19. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
    Inman BA; Longo TA; Ramalingam S; Harrison MR
    Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
    Aragon-Ching JB; Trump DL
    Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.